articleMMWR Morbidity and Mortality Weekly ReportSep 12, 2024DIAMOND OA

Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024

MKMiwako KobayashiAJAndrew J. LeidnerRGRyan GierkeJLJennifer L. FarrarRLRebecca L. Morgan
PubMed
Indexed incrossrefpubmed

Abstract

On June 17, 2024, the Food and Drug Administration approved 21-valent pneumococcal conjugate vaccine (PCV) (PCV21; CAPVAXIVE; Merck Sharp & Dohme, LLC) for adults aged ≥18 years. PCV21 does not contain certain serotypes that are included in other licensed pneumococcal vaccines but adds eight new serotypes. The Advisory Committee on Immunization Practices (ACIP) recommends use of a PCV for all adults aged ≥65 years, as well as adults aged 19-64 years with certain risk conditions for pneumococcal disease if they have not received a PCV or whose vaccination history is unknown. Previously, options included either 20-valent PCV (PCV20; Prevnar20; Wyeth Pharmaceuticals, Inc.) alone or a 15-valent PCV (PCV15;…

Citation impact

110
total citations
FWCI
38.73
Percentile
100%
References
4
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Pneumococcal conjugate vaccine
  • Advisory committee
  • Immunization
  • Pneumococcal disease
  • Conjugate
  • Medicine
  • Political science
  • Environmental health
No related works found for this paper.

Funding